BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Cantor Fitzgerald
Fish and Richardson
Boehringer Ingelheim
Merck
Medtronic
Deloitte
Queensland Health
Teva
Dow

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,792,795

« Back to Dashboard

Which drugs does patent 5,792,795 protect, and when does it expire?

Patent 5,792,795 protects EPANOVA and is included in one NDA.

This patent has twenty-nine patent family members in twenty-three countries.
Summary for Patent: 5,792,795
Title: Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
Abstract:Inflammatory bowel disease, especially Crohn's disease and ulcerative colitis, is treated by administration of an oral dosage form, containing as an active principle an omega-3 polyunsaturated acid in free acid form or as a pharmaceutically acceptable salt thereof, which releases the acid in the ileum. Preferably the oral dosage form is a gelatine capsule coated with a poly(ethylacrylate-methylmethacrylate).
Inventor(s): Buser; Thomas (Ziefen, CH), Camporesi; Emilio P. (Ziefen, CH)
Assignee: Tillotts Pharma AG (Ziefen, CH)
Application Number:08/687,329
Patent Claim Types:
see list of patent claims
Use; Compound; Dosage form;

Drugs Protected by US Patent 5,792,795

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca Pharms EPANOVA omega-3-carboxylic acids CAPSULE;ORAL 205060-001 May 5, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,792,795

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9509764May 15, 1995
PCT Information
PCT FiledMay 13, 1996PCT Application Number:PCT/EP96/02038
PCT Publication Date:November 21, 1996PCT Publication Number: WO96/36329

Non-Orange Book US Patents Family Members for Patent 5,792,795

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,948,818 Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 5,792,795

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2221356 ➤ Subscribe
China 1184421 ➤ Subscribe
China 1104237 ➤ Subscribe
Czech Republic 9703607 ➤ Subscribe
Czech Republic 288560 ➤ Subscribe
Germany 69634693 ➤ Subscribe
Denmark 0825858 ➤ Subscribe
European Patent Office 0825858 ➤ Subscribe
Hungary 9900337 ➤ Subscribe
United Kingdom 9509764 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
US Department of Justice
Boehringer Ingelheim
Express Scripts
Moodys
Julphar
Healthtrust
Cantor Fitzgerald
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot